Investors
Join us
Khloris is the first and only company to develop an iPSC-derived whole cell vaccine for the treatment of cancer. Fundamentally differentiated from previous cancer vaccinations, iPSC vaccination combines key mechanistic elements to boost anti-tumor immunity. Presenting a broad spectrum of oncofetal and other cancer-related antigens, iPSC vaccination fully mobilizes the immune system.
Khloris is also developing iPSC-derived cardiomyocytes as a novel cell therapy treatment for patients with cardiovascular diseases.
